Kinase Modulating Compounds for Selective Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective compounds and methods for modulating receptor protein kinases, which are associated with various disease states such as cancer, autoimmune diseases, and inflammatory disorders.
Innovation Solution
A compound of formula I, along with its pharmaceutically acceptable salts, hydrates, solvates, tautomers, and isomers, is provided. This compound selectively modulates kinases, offering potential therapeutic benefits for diseases related to kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing kinase inhibitors are used, then some kinase activity can be inhibited, but they lack selectivity and cause off-target effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (formula I) that create unique binding interactions with particular kinase residues. The substituents at specific positions (R1-R9) are optimized to provide selective interactions with the ATP binding site of target kinases while avoiding off-target effects, achieving high selectivity through localized molecular features.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize kinase selectivity. By adjusting parameters such as the nature of R1-R9 substituents and their spatial arrangements, the compounds achieve differentiated binding affinities for specific kinases while maintaining low affinity for off-target kinases.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are developed, then multiple kinases can be inhibited, but specificity for particular disease targets is reduced
Solution Approach 1:
The patent applies universality through a unified chemical framework (formula I) that can target multiple kinases involved in different disease pathways. The core structure provides a universal binding mode while allowing customization through substituent variation to achieve disease-specific selectivity, enabling one framework to address multiple therapeutic indications.
Solution Approach 2:
The patent uses segmentation by dividing the kinase inhibition strategy into disease-specific subgroups. Different embodiments of formula I are optimized for specific kinase families (e.g., Src family, Abl family, FGFR) involved in different diseases, allowing the broad framework to be segmented into disease-targeted therapies with high specificity.
3Reliability
If new kinase modulators are synthesized, then therapeutic efficacy can be improved, but development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by establishing a comprehensive structure-activity relationship (SAR) framework before clinical development. Extensive in silico modeling and preliminary in vitro data are generated to identify optimal substituents and configurations, allowing the most promising compounds to be selected for advanced development without time-consuming trial-and-error synthesis.
Solution Approach 2:
The patent employs copying by utilizing known kinase inhibitor structures as templates while introducing modifications to achieve superior selectivity and efficacy. The formula I framework copies successful binding motifs from existing literature while adding novel features that enhance therapeutic performance, accelerating development by building on established knowledge.
Data Source
AI summary
Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.